Every Form 4 that Editas Medicine, Inc. (EDIT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine, Inc. (EDIT) reported that EVP and Chief Medical Officer Daniel Scott Ory received a grant of stock options covering 950,000 shares of common stock on September 8, 2026. The options have an exercise price of $3.03 per share and are scheduled to vest over four years, with 25% vesting on October 15, 2027 and the remaining 75% vesting in equal monthly installments through October 15, 2030. Following this grant, he holds 950,000 stock options directly, which expire on September 7, 2036.
Editas Medicine, Inc. (EDIT) reported that EVP and Chief Scientific Officer Linda Burkly sold 709 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share, in an open-market transaction.
According to the company’s disclosures, the sale was effected under a durable automatic sales instruction plan adopted on July 3, 2023 and represents shares sold by Editas Medicine to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 2, 2026, rather than a discretionary trade by Burkly. After this transaction, she held 61,660 shares of Editas Medicine common stock directly. The transaction price reflects a weighted average for multiple trades executed between $3.0050 and $3.0372 per share.
Editas Medicine, Inc. (EDIT) reported that its SVP, Chief Financial Officer, Amy Parison, sold 453 shares of common stock on September 3, 2026 at an average price of $3.04 per share. The transaction was executed under a durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following this sale, Parison directly holds 13,839 shares of Editas Medicine common stock.
Editas Medicine, Inc. (EDIT) director and CEO O'Neill Gilmore Neil reported selling 5,124 shares of common stock on September 3, 2026 at a weighted average price of $3.0372 per share in open-market trades. The sale was made under a Rule 10b5-1 durable automatic sales instruction plan adopted on April 13, 2022 to satisfy tax withholding obligations from restricted stock units that vested on September 2, 2026, and is described as non-discretionary. Following the sale, the reporting person directly holds 243,189 shares of Editas Medicine common stock.
Editas Medicine, Inc. reported that director Ellinor Patrick Thomas II received a grant of stock options covering 103400 shares of common stock. The options have an exercise price of $2.9000 per share, expire on 2036-08-05, and vest in three equal annual installments from 2027-08-06 through 2029-08-06. Following the grant, the director holds 103400 derivative securities directly.
Editas Medicine, Inc. executive Amy Parison, SVP and Chief Financial Officer, reported the sale of 678 shares of common stock on August 3, 2026 at $2.58 per share. The sale was executed under a Rule 10b5-1 durable automatic sales instruction plan adopted on July 7, 2022 to satisfy tax withholding obligations arising from restricted stock units that vested on August 1, 2026 and was not a discretionary trade. Following this transaction, she directly holds 14,292 shares of Editas Medicine common stock.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly sold 4,928 shares of common stock at $2.67 per share on July 28, 2026. The sale was executed under a durable Rule 10b5-1 automatic sales plan to cover tax withholding from restricted stock units vesting on July 24, 2026 and was not a discretionary trade. Following this transaction, Burkly directly held 62,369 shares of Editas Medicine common stock.
Editas Medicine, Inc. director Bernadette Connaughton received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share, are scheduled to vest in full on June 17, 2027, and expire on June 16, 2036. Following this compensation award, she holds 51,700 derivative securities directly, with no open-market buy or sell reported.
Editas Medicine director Jessica Hopfield received a new stock option grant. On June 17, 2026, she was awarded options to acquire 51,700 shares of Editas Medicine common stock at an exercise price of $2.55 per share.
The option is scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this grant, she holds options covering 51,700 shares directly as reported in this filing.
Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation. The award covers 51,700 options to buy Editas Medicine common stock at an exercise price of $2.55 per share. The option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027, with an expiration date of June 16, 2036. Following this grant, Hirsch holds 51,700 stock options directly, and there were no open‑market stock purchases or sales reported in this filing.
Editas Medicine, Inc. director David Scadden received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and expire on June 16, 2036. They were granted on June 17, 2026 and are scheduled to vest in full on June 17, 2027. Following this grant, Scadden holds 51,700 stock options directly.
Editas Medicine director Elliott M. Levy received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and were granted on June 17, 2026. They are scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this award, Levy holds 51,700 derivative securities directly.
Editas Medicine, Inc. senior vice president and chief financial officer Amy Parison reported an open-market sale of 464 shares of common stock on June 3, 2026 at a weighted average price of $2.7010 per share. According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 7, 2022 and was made to satisfy tax withholding obligations arising from vesting of restricted stock units on June 2, 2026, rather than as a discretionary trade. Following this transaction, she directly holds 14,970 shares of Editas Medicine common stock.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic, tax-related share sale. On June 3, 2026, he sold 15,380 shares of common stock at a weighted average price of $2.7011 per share, leaving 248,313 shares owned directly.
The sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022, and was made to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. The footnote states this was not a discretionary trade by the CEO.
Editas Medicine, Inc. executive Linda Burkly reported an open-market sale of common stock. She sold 731 shares on June 3, 2026 at a weighted average price of $2.7011 per share. After this transaction, she directly holds 67,297 shares of Editas Medicine common stock.
According to the footnotes, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023. The shares were sold to cover tax withholding obligations arising from restricted stock units that vested on June 2, 2026, and the filing states the trade was not discretionary.
Editas Medicine, Inc. reported that CEO O'Neill Gilmore Neil received a grant of stock options covering 1,015,200 shares of common stock at an exercise price of $2.54 per share. The options were granted as compensation and have no purchase price at grant.
The award is scheduled to vest over four years in equal monthly installments, beginning on April 12, 2026 and continuing through March 12, 2030, aligning the CEO’s long-term incentives with company performance over that period.
Editas Medicine, Inc. reported that its SVP and Chief Financial Officer, Amy Parison, received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and were granted as a compensation award, not an open-market purchase.
According to the disclosure, the options were granted on March 12, 2026 and are scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this award, she holds 292,856 option-based rights to acquire Editas Medicine common shares directly.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and expire on March 11, 2036.
The award was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this grant, Burkly holds 292,856 stock options from this award.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic tax-related share sale. On March 3, 2026, he sold 5,394 shares of Editas Medicine common stock in open-market transactions at a weighted average price of $2.0197 per share. The footnotes explain the sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022 to cover tax withholding on restricted stock units that vested on March 2, 2026, and did not represent a discretionary trade. Following this transaction, he held 263,693 shares of common stock directly.
Editas Medicine, Inc. Senior Vice President and Chief Financial Officer Amy Parison reported an open-market sale of 474 shares of common stock at a weighted average price of $2.02 per share on March 3, 2026. According to the disclosure, the sale was executed under a durable automatic sales instruction plan adopted on July 7, 2022 and was made solely to cover tax withholding obligations arising from restricted stock units that vested on March 2, 2026, rather than as a discretionary trade. After this transaction, Parison directly owned 15,434 shares of Editas Medicine common stock.
Editas Medicine, Inc. executive Linda Burkly, EVP and Chief Scientific Officer, reported an open-market sale of 749 shares of common stock at a weighted average price of $2.0196 per share. After this transaction, she held 68,028 shares of Editas Medicine common stock.
According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023 and was made to cover tax withholding obligations from restricted stock units that vested on March 2, 2026. The filing states that this was not a discretionary trade by the reporting person.